Idera Pharmaceuticals

Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the research and development of medications for rare and orphan diseases. The firm’s product portfolio includes ACG-801 and ACG-701, which targets Farber Disease, Melioidosis, and Cystic Fibrosis. The company was founded in 1989 and is headquartered in Exton, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the research and development of medications for rare and orphan diseases. The firm's product portfolio includes ACG-801 and ACG-701, which targets Farber Disease, Melioidosis, and Cystic Fibrosis. The company was founded in 1989 and is headquartered in Durham, NC.

Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024

Idera Pharmaceuticals Acquires Aceragen

EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022.

Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results

TAL Education Group

Verb Technology Company Inc

What you need to know about trading penny stocks right now The post Buying Penny Stocks Right Now? 3 Top Tips to Know  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Buying Penny Stocks Right Now? 3 Top Tips to Know

Vinco Ventures

Are these three penny stocks on your watchlist right now? The post 3 Penny Stocks That Are Climbing During Today's Market Selloff appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Are Climbing During Today's Market Selloff

Idera Pharmaceuticals Inc (NASDAQ: IDRA) shared positive interim results from its investigator-sponsored Phase 2 trial, INTRIM 1, involving tilsotolimod, Idera's synthetic Toll-like receptor 9 agonist.  Based on these results, the trial has been stopped early.

Why Are Idera Pharmaceuticals Shares Soaring Today

– Enrollment Stopped Early for Efficacy – – Enrollment Stopped Early for Efficacy –

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC

EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2022.

Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Acutus Medical

Brickell Biotech Inc

Histogen

Synthetic Biologics

Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Biotech Penny Stocks Under $1 To Watch This Week

EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2021.

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Caladrius Biosciences

Flotek Industries

Gran Tierra Energy

Penny stocks to buy for under $2 The post Hot Penny Stocks For 2022 To Buy For Under $2 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks For 2022 To Buy For Under $2

EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist.

Idera Pharmaceuticals Announces Tilsotolimod Updates

Arbutus Biopharma

Biofrontera

ReWalk Robotics

SPI Energy

Analysts are bullish on these penny stocks in 2021. Should you be?

5 Penny Stocks To Buy According To Analysts & Targets Up To 341%

EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2021.

Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021.

Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares are trading higher by 43% at $1.60 after it was disclosed in a Form 4 filing the company COO Daniel Soland purchased 50,000 shares of the company stock at an average price of $1.19. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of innovative therapeutics for oncology and rare diseases.

Why Idera Shares Are Skyrocketing Today

The stock price of Idera Pharmaceuticals Inc (NASDAQ: IDRA) increased by over 20% pre-market. This is why it happened.

IDRA Stock Price Increases Over 20% Pre-Market: Why It Happened

Idera Pharmaceuticals Inc (NASDAQ: IDRA) has decided not to continue the ILLUMINATE-301 Phase 3 trial evaluating tilsotolimod in melanoma to its overall survival (OS) primary endpoint. The trial assessed tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma.

Idera Will Not Continue Tilsotolimod/Ipilimumab Combo Melanoma Trial Into OS Primary Endpoint

EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company's trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, to its overall survival (OS) primary endpoint. The Company reported in March 2021 that the trial did not meet its primary endpoint of objective response rate (ORR). Full results from the study will be presented in a future publication.

Idera Pharmaceuticals Announces Corporate Updates

EXTON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2021.

Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

The stock price of Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) fell by 62% on March 19. This is why it happened.

IDRA Stock Price Fell 62%: Why It Happened

SenesTech

China Rapid Finance

Even the best penny stocks have their dog days. Here's a celebration of this week's weirdest plays: SNES, IDRA, SOS, TSNPD and HLLPF.

Tomslist: The 5 Weirdest Penny Stock Stories of the Week

The company's experimental cancer drug flopped in a late-stage study.

Why Idera Pharmaceuticals Stock Is Crashing Today

The stock price of Idera Pharmaceuticals Inc (NASDAQ: IDRA) fell by over 60% pre-market. This is why it happened.

IDRA Stock Price Falls Over 60% Pre-Market: Why It Happened

Shares of Idera Pharmaceuticals Inc. plummeted 63.3% in active trading to pace all premarket decliners, after the immunotherapy company said the ILLUMINATE-301 pivotal registration trial of its treatment of patients with anti-PD-1 refractory advanced melanoma failed to meet its primary endpoint of objective response rate. Trading volume spiked to 6.0 million shares ahead of the open, compared with the full-day average of about 1.1 million shares over the past 30 days.

Idera Pharmaceuticals stock plunges after disappointing trial results, prompting analyst downgrade

Shares of Idera Pharmaceuticals Inc. (NASDAQ: IDRA) plunged more than 62% in the extended session Thursday after the biopharmaceutical company said its lead drug candidate Tilsotolimod failed to meet the primary endpoint in a Phase 3 trial for anti-PD-1 refractory advanced melanoma. What Happened: Idera Pharmaceuticals said that ILLUMINATE-301 is a Phase 3 trial evaluating tilsotolimod in combination with Bristol-Myers Squibb Company's (NYSE: BMY) Yervoy (ipilimumab) against ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma.

News for Idera Pharmaceuticals Stock (IDRA)